1-3 of 3
Christoph von Schilling, MD, PHD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD PhD, Mathias J. Rummel, MD PhD, Antonio Pezzutto, MD PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD PhD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2007) 110 (11): 4501.
https://doi.org/10.1182/blood.V110.11.4501.4501
Published: 2007
Journal Articles

Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals.

Angela Ihbe-Heffinger, MS, PhD, Bernadette Paessens, MS, Volker R. Jacobs, MD, PhD, MBA, Birgit Ehlken, MS, Margarita Shlaen, MPH, Karin Berger, MPH, Rudolf Bernard, MS, Christian Peschel, MD, PhD, Anita Goertz, MS, MPH, Christoph von Schilling, MD, PHD
Journal: Blood
Blood (2007) 110 (11): 3338.
https://doi.org/10.1182/blood.V110.11.3338.3338
Published: 2007
Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem Cell Transplantation (ASCT) - A Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD, PhD, Mathias J. Rummel, MD, PhD, Antonio Pezzutto, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD, Martin Dreyling, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 4786.
https://doi.org/10.1182/blood.V106.11.4786.4786
Published: 2005